Nonsentinel Lymph Nodes Predict Melanoma Prognosis

This article originally appeared here.
Share this content:
Nonsentinel Lymph Nodes Key Factor in Melanoma Prognosis
Nonsentinel Lymph Nodes Key Factor in Melanoma Prognosis

(HealthDay News) -- Nonsentinel lymph node (NSLN) positivity is a significant prognostic factor in patients with stage III melanoma, associated with shorter overall and disease-specific survival, according to research published online July 31 in JAMA Surgery.

Anna M. Leung, M.D., of St. John's Health Center in Santa Monica, Calif., and colleagues searched the database at the John Wayne Cancer Institute and identified patients with sentinel lymph nodes (SLNs) positive for cutaneous melanoma who subsequently underwent completion lymph node dissection. The survival associated with disease limited to SLNs and disease spread into NSLNs was examined.

The researchers found that 329 of 4,223 patients who underwent SLN biopsy from 1986 to 2012 had a tumor-positive SLN. Of these, 250 patients (76.0%) had no additional positive nodes and 79 patients (24.0%) had a tumor-positive NSLN.

The NSLN-positive group had shorter overall median survival (42.2 versus 178 months), lower rate of five-year overall survival (46.4% versus 72.3%), shorter median melanoma-specific survival (60 months versus not yet reached), and lower rate of five-year melanoma-specific survival (49.5% versus 77.8%) than the SLN-only positive group.

"We propose that, for the next iteration of the staging system, the committee performs an analysis of the independent prognostic impact of NSLN status," the authors write.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs